## PAR Concept Reissuances

Dr. Shamala Srinivas
Associate Director
Office of Referral, Review and
Program Coordination

## NOFOs for Reissuance (20 Concepts: 29 individual NOFOs)

PRIMARY DOC	Current NOFO Number	Title of the NOFO	Activity Code	First Issued	Date of Issue	<b>Expiration Date</b>	Number of Prior Issuances	Number of Grants Awarded
DCB	PAR-20-131	Research Projects to Enhance Applicability of Mammalian Models for Translational Research	R01	14-May-14	12-Mar-20	8-May-23	3	22
DCCPS	PAR-21-341	Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)	R21	8-Apr-16	21-Oct-21	8-Oct-24	2	21
DCCPS	PAR-21-190	Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)	R01	24-Jul-19	12-Mar-21	7-Mar-24	1	49
DCCPS	PAR-20-276	Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)	R01	30-Mar-17	22-Jul-20	8-Jan-23	1	14
DCCPS	PAR-20-277	Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)	R21	30-Mar-17	22-Jul-20	8-Jan-23	1	9
DCP, DCCPS	PAR-21-035	Cancer Prevention and Control Clinical Trials Program (R01 Clinical Trial Required)	R01	5-Jan-18	12-Nov-20	8-Jan-24	1	46
DCTD	PAR-20-305	Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, 2023 (P50 Clinical Trial Required)	P50	20-Jun-01	28-Sep-20	8-Jan-24	13	11
DCTD	PAR-21-166; PAR-20- 155	Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed/Optional)	R01; R01	6-Feb-15	25-Mar-21	5-Mar-24	3	15
DCTD	PAR-20-284	Innovative Research in Cancer Nanotechnology (IRCN)	R01	30-Mar-17	13-Aug-20	5-May-23	2	10
DCTD	PAR-20-271	Assay development and screening for discovery of chemical probes or drugs	R01	17-Jul-17	20-Jul-20	8-Jan-23	1	15
DCTD	PAR-21-033	National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)	R01	15-Jan-18	10-Nov-20	8-Jan-24	2	59
DCTD, DCP	PAR-20-313	Assay Validation of High-Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)	UH2/UH3	21-Jan-15	13-Oct-20	11-Oct-23	3	25
DCTD, DCP	PAR-20-314	Assay Validation of High-Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)	UH3	21-Jan-15	13-Oct-20	11-Oct-23	3	5
DCTD, DCP	PAR-23-088	Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)	R01	October 4, 2016	6-Jan-23	28-Oct-23	3	8
DCTD, DCB, DCP	PAR-20-155	Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)	R01	21-Dec-16	30-Mar-20	8-Sep-22	1	24

PRIMARY DOC	Current NOFO Number	Title of the NOFO	Activity Code	First Issued	Date of Issue	Expiration Date	Number of Prior Issuances	Number of Grants Awarded
OD-CCT	PAR-21-128	The NCI Transition Career Development Award (Independent Clinical Trial Not Allowed)	K22	4-May-99	15-Mar-21	15-Mar-24	5	11
OD-CCT	PAR-21-111	The NCI Transition Career Development Award (K22 Independent Clinical Trial Required)	K22	6-Dec-17	15-Mar-21	15-Mar-24	1	0
OD-CCT	PAR-21-318	The NCI Transition Career Development Award (Independent Basic Experimental Studies with Humans Required)	K22	10-Sep-21	15-Mar-21	15-Mar-24	0	0
OD-CCT	PAR-22-136	Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)	K12	23-Apr-04	11-Apr-22	18-Jun-24	6	5
OD-CCT	PAR-21-065	Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)	R25	24-Mar-15	17-Nov-20	8-Jan-24	2	2
OD-CCT	PAR-21-066	Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)	R25	24-Mar-15	17-Nov-20	8-Sep-24	2	3
OD-CCT	PAR-21-067	Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)	R25	24-Mar-15	17-Nov-20	8-Sep-24	2	5
OD-CRCHD	PAR-21-061	Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)	R21	11-Jun-09	18-Mar-21	18-Nov-23	5	9
OD-CRCHD	PAR-22-239	Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20 Clinical Trial Not Allowed)	P20	22-Feb-07	26-Oct-22	7-Jan-23	5	0 (review June 2023)
OD-CRCHD	PAR-22-249	Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)	U54	9-Dec-11	26-Oct-22	7-Jan-23	4	0 (review June 2023)
OD-CSSI	PAR-22-187	NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed)	R50	9-Jan-16	25-May-22	3-Nov-22	7	7
OD-CSSI	PAR-22-188	NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed)	R50	9-Jan-16	25-May-22	3-Nov-22	7	6
OD-CSSI	PAR-21-285	NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed)	R50	9-Jan-16	21-Jul-21	2-Nov-21	6	9
OD-CSSI	PAR-21-286	NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed)	R50	9-Jan-16	21-Jul-21	2-Nov-21	6	5
OD-CSSI	PAR-20-287	NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed)	R50	9-Jan-16	20-Aug-20	5-Jan-21	5	6
OD-CSSI	PAR-20-288	NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed)	R50	9-Jan-16	20-Aug-20	5-Jan-21	5	9
OD-OCC	PAR-21-306	NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)	R50	7-Oct-23	20-Aug-21	7-Jan-22	0	23